NYSE - Delayed Quote USD

Pfizer Inc. (PFE)

Compare
29.01 +0.29 (+1.01%)
At close: August 30 at 4:02 PM EDT
29.04 +0.03 (+0.10%)
After hours: August 30 at 8:00 PM EDT
Loading Chart for PFE
DELL
  • Previous Close 28.72
  • Open 28.72
  • Bid 29.03 x 3000
  • Ask 29.05 x 2900
  • Day's Range 28.67 - 29.05
  • 52 Week Range 25.20 - 36.29
  • Volume 20,726,282
  • Avg. Volume 32,225,652
  • Market Cap (intraday) 164.391B
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) --
  • EPS (TTM) -0.46
  • Earnings Date Oct 29, 2024 - Nov 4, 2024
  • Forward Dividend & Yield 1.68 (5.79%)
  • Ex-Dividend Date Jul 26, 2024
  • 1y Target Est 33.01

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

88,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PFE

View More

Performance Overview: PFE

Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PFE
5.29%
S&P 500
18.42%

1-Year Return

PFE
15.02%
S&P 500
25.59%

3-Year Return

PFE
29.18%
S&P 500
25.26%

5-Year Return

PFE
6.59%
S&P 500
93.14%

Compare To: PFE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PFE

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    164.39B

  • Enterprise Value

    225.97B

  • Trailing P/E

    --

  • Forward P/E

    11.25

  • PEG Ratio (5yr expected)

    0.24

  • Price/Sales (ttm)

    2.97

  • Price/Book (mrq)

    1.87

  • Enterprise Value/Revenue

    4.10

  • Enterprise Value/EBITDA

    41.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.70%

  • Return on Assets (ttm)

    0.94%

  • Return on Equity (ttm)

    -2.74%

  • Revenue (ttm)

    55.17B

  • Net Income Avi to Common (ttm)

    -2.59B

  • Diluted EPS (ttm)

    -0.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.1B

  • Total Debt/Equity (mrq)

    79.41%

  • Levered Free Cash Flow (ttm)

    3.44B

Research Analysis: PFE

View More

Company Insights: PFE

Research Reports: PFE

View More

People Also Watch